The 20 most recent market catalysts affecting $CLDX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88
Leerink Partners, through analyst Thomas Smith, has raised its price target for Celldex Therapeutics (CLDX) from $70 to $88 while maintaining an 'Outperform' rating. This action in…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
Morgan Stanley's analyst Judah Frommer has raised the price target for Celldex Therapeutics (CLDX) from $50 to $57 while maintaining an 'Overweight' rating. This action signals inc…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 85
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
Celldex Therapeutics reported highly positive Phase 3 trial results for barzolvolimab, a potential treatment for chronic spontaneous urticaria (CSU). Both EMBARQ-CSU1 and EMBARQ-CS…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64
HC Wainwright & Co. analyst Joseph Pantginis has maintained a 'Buy' rating on Celldex Therapeutics (CLDX) and significantly raised the price target from $42 to $64. This upward rev…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Cantor Fitzgerald analyst Kristen Kluska has reiterated an 'Overweight' rating on Celldex Therapeutics (CLDX) and raised the price target from $61 to $72. This action signals conti…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 95
Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU
Celldex Therapeutics reported overwhelmingly positive topline results from its two Phase 3 trials for barzolvolimab, a drug targeting chronic spontaneous urticaria (CSU). The trial…
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50
Morgan Stanley analyst Judah Frommer has maintained an 'Overweight' rating on Celldex Therapeutics (CLDX) and raised the price target from $46 to $50. This action signals a continu…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46
Morgan Stanley analyst Judah Frommer maintained an 'Overweight' rating on Celldex Therapeutics and raised the price target from $40 to $46. This action signals increased analyst co…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Barclays analyst Etzer Darout has maintained an 'Overweight' rating on Celldex Therapeutics (CLDX) and raised the price target from $48 to $53. This action signals a positive outlo…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics' Q2 earnings report presents a mixed picture, but the overwhelming negative is the massive sales miss. While beating EPS estimates by narrowing losses is a pos…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on Celldex Therapeutics (CLDX) and raised the price target from $48 to $72. This significant increase in the pri…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 55
Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $48
Wells Fargo analyst Derek Archila maintained an 'Overweight' rating on Celldex Therapeutics (CLDX) but lowered the price target from $54 to $48. This event is significant because w…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 55
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $40
Morgan Stanley analyst Judah Frommer maintained an 'Overweight' rating on Celldex Therapeutics, signaling continued confidence in the company's long-term prospects. However, the pr…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 55
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $61
Cantor Fitzgerald analyst Kristen Kluska maintained an 'Overweight' rating on Celldex Therapeutics, signaling continued confidence in the company's long-term prospects. However, th…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 85
Celldex Therapeutics shares are trading lower after the company reported that the Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis did not meet its primary endpoint. Also, Canaccord Genuity lowered its price target on the stock from $62 to $60.
The failure of a Phase 2 clinical trial for barzolvolimab is a major setback for Celldex Therapeutics, as it represents a significant investment that did not yield the desired resu…
Jul 22, 2026
Corporate Catalyst
Bearish
Impact 85
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study
Celldex Therapeutics announced the discontinuation of its Phase 2 clinical trial for barzolvolimab in prurigo nodularis because the drug did not show meaningful improvement over pl…
Jul 21, 2026
Corporate Catalyst
Bearish
Impact 95
Celldex Therapeutics shares are trading lower after the company reported that the Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis did not meet its primary endpoint.
The failure of a Phase 2 clinical trial for a significant drug candidate like barzolvolimab is a major negative catalyst for Celldex Therapeutics. This directly impacts the company…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $100
Guggenheim analyst Yatin Suneja has maintained a 'Buy' rating on Celldex Therapeutics (CLDX) and raised the price target from $90 to $100. This upgrade suggests that the analyst se…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 55
Celldex Therapeutics shares are trading lower. The company announced that its CFO, Sam Martin, has informed the company of his plans to retire in 2027
The retirement of a CFO, especially from a biotechnology company like Celldex Therapeutics, can raise questions about the company's long-term financial planning and strategic direc…
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 55
Celldex CFO Sam Martin Plans To Retire In 2027
Celldex (CLDX) has disclosed that its long-serving CFO, Sam Martin, plans to retire in March 2027. This is a forward-looking announcement, providing the company with over three yea…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.